Conference Agenda

In order to face the environmental, economic and social problems linked to high consumption and intense manufacturing, Europe, ecological associations propose scenarios for the implementation of the circular economy, without saying how to implement them. Several circular strategies (CS) (reuse, remanufacturing, recycling...) allow to regenerate a product and its components throughout its life cycle. Currently,

these CS are not implemented in a systemic way, but in a punctual and individual way. The objective is to deepen the knowledge of the global implementation of several CS. To achieve this, the paper proposes to characterise each CS according to the requirements of the products entering and leaving. This technical characterisation allows us to analyse their complementarities and interactions. This characterisation will be illustrated on the example of remanufacturing and resynthesis. Then, an analysis of our proposal is realized to show the contributions in order to have a holistic approach of the regeneration.

Only a few studies discuss the applications of industry 4.0 and Industry 5.0 in the context of end-of-life aircraft treatment. This paper aims to discuss the implications of these technologies in end-of-life aircraft processes. The selected technologies including blockchain, the internet of things, digital twins, big data, artificial intelligence, augmented/virtual reality, collaborative robots and Industry 5.0 are discussed. In addition, the criteria to evaluate the different technologies and a conceptual model for selecting the core technologies will be presented.

Pharmaceutical industries play an integral role in our society as their primary purpose is to provide products that enhance human health and well-being. Due to its intrinsic activities, the impact of the healthcare sector on the environment is consequent. However, the preservation of our environment is a prerequisite to ensure human health resilience.

The circular economy (CE) is a model of production and consumption aimed to preserve environmental sustainability. The CE principles, such as “Re-duce, Reuse, Recycle” (Kirchherr et al., 2017; Ellen MacArthur Foundation, 2013; Ardolino et al., 2022) are required in an expanding world where resources are limited (Panza et al., 2022), and the generation of waste increases each year. Considering the size of the pharmaceutical sector in the global economy and the fact that less than 10% of our economy is circular (Circle Economy, 2022), it is essential to implement the concept of circularity to limit the tremendous resource consumption. Nevertheless, most of the work that has been done in this area focuses on a few specific steps of drug and medical device development processes (Ang et al., 2020; Ranjbari et al., 2022), creating room for implementation opportunities.

The goal of this paper is to provide a mapping of the research that has been done in the field of CE, related to the pharmaceutical sector. As circularity is driven by design, this paper focuses on the whole value chain of pharmaceutical products, from raw material extraction to the end of life. The findings of this study are categorized regarding product life-cycle steps. This allows the identification of current research trends and opportunities for future research and potential circular solutions.